Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM).
KRASG12C mutation
chemotherapy
first line treatment
mCRC
real-world data
Journal
ESMO open
ISSN: 2059-7029
Titre abrégé: ESMO Open
Pays: England
ID NLM: 101690685
Informations de publication
Date de publication:
10 2022
10 2022
Historique:
received:
29
06
2022
revised:
16
07
2022
accepted:
19
07
2022
pubmed:
23
8
2022
medline:
25
10
2022
entrez:
22
8
2022
Statut:
ppublish
Résumé
The presence of KRASG12C mutation in metastatic colorectal cancer (mCRC) correlates with poor outcome. Although different selective inhibitors are under clinical development, the optimal treatment remains uncertain. Thus, we conducted a retrospective analysis in a large cohort of patients with KRASG12C mCRC treated in 12 Italian oncology units. Patients with unresectable mCRC harboring KRASG12C mutation receiving a first-line chemotherapy doublet or triplet between 2011 and 2021 were included in the study. Evaluation of overall response rate (ORR), progression-free survival (PFS) and overall survival (OS) analysis was carried out. A total of 256/6952 (3.7%) patients with mCRC displayed KRASG12C mutation; of these, 111 met the inclusion criteria. The ORR of first-line therapy was 38.7% (43/111). Median PFS (mPFS) was 9 months [95% confidence interval (CI) 7.5-10.5 months]. After progression, only 62% and 36% of the patients are fit to receive second or third lines of treatment, with limited clinical benefit. Median OS (mOS) was 21 months (95% CI 17.4-24.6 months). In patients receiving first-line triplet chemotherapy, ORR was 56.3% (9/16), mPFS was 13 months (95% CI 10.3-15.7 months) and mOS was 32 months (95% CI 7.7-56.3 months). For irinotecan-based doublets, ORR was 34.5 (10/29), mPFS was 9 months (95% CI 6.4-11.6 months) and mOS was 22 months (95% CI 16.0-28.0 months). With oxaliplatin-based doublets ORR was 36.4% (24/62), mPFS was 7 months (95% CI 4.6-9.4 months) and mOS was 18 months (95% CI, 13.6-22.4 months). Patients with KRASG12C-mutant mCRC had a disappointing response to standard treatments. Within the limitations of a retrospective study, these results suggest that first-line chemotherapy intensification with FOLFOXIRI is a valid option in fit patients.
Sections du résumé
BACKGROUND
The presence of KRASG12C mutation in metastatic colorectal cancer (mCRC) correlates with poor outcome. Although different selective inhibitors are under clinical development, the optimal treatment remains uncertain. Thus, we conducted a retrospective analysis in a large cohort of patients with KRASG12C mCRC treated in 12 Italian oncology units.
PATIENTS AND METHODS
Patients with unresectable mCRC harboring KRASG12C mutation receiving a first-line chemotherapy doublet or triplet between 2011 and 2021 were included in the study. Evaluation of overall response rate (ORR), progression-free survival (PFS) and overall survival (OS) analysis was carried out.
RESULTS
A total of 256/6952 (3.7%) patients with mCRC displayed KRASG12C mutation; of these, 111 met the inclusion criteria. The ORR of first-line therapy was 38.7% (43/111). Median PFS (mPFS) was 9 months [95% confidence interval (CI) 7.5-10.5 months]. After progression, only 62% and 36% of the patients are fit to receive second or third lines of treatment, with limited clinical benefit. Median OS (mOS) was 21 months (95% CI 17.4-24.6 months). In patients receiving first-line triplet chemotherapy, ORR was 56.3% (9/16), mPFS was 13 months (95% CI 10.3-15.7 months) and mOS was 32 months (95% CI 7.7-56.3 months). For irinotecan-based doublets, ORR was 34.5 (10/29), mPFS was 9 months (95% CI 6.4-11.6 months) and mOS was 22 months (95% CI 16.0-28.0 months). With oxaliplatin-based doublets ORR was 36.4% (24/62), mPFS was 7 months (95% CI 4.6-9.4 months) and mOS was 18 months (95% CI, 13.6-22.4 months).
CONCLUSION
Patients with KRASG12C-mutant mCRC had a disappointing response to standard treatments. Within the limitations of a retrospective study, these results suggest that first-line chemotherapy intensification with FOLFOXIRI is a valid option in fit patients.
Identifiants
pubmed: 35994791
pii: S2059-7029(22)00195-8
doi: 10.1016/j.esmoop.2022.100567
pmc: PMC9588891
pii:
doi:
Substances chimiques
Oxaliplatin
04ZR38536J
Irinotecan
7673326042
Fluorouracil
U3P01618RT
Types de publication
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
100567Informations de copyright
Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Références
J Exp Clin Cancer Res. 2018 Mar 13;37(1):57
pubmed: 29534749
Nat Rev Clin Oncol. 2021 Aug;18(8):506-525
pubmed: 33864051
N Engl J Med. 2020 Sep 24;383(13):1207-1217
pubmed: 32955176
CA Cancer J Clin. 2022 Jul;72(4):372-401
pubmed: 35472088
Lancet Oncol. 2015 Oct;16(13):1306-15
pubmed: 26338525
Clin Colorectal Cancer. 2017 Dec;16(4):372-376
pubmed: 28465170
N Engl J Med. 2021 Jan 14;384(2):185-187
pubmed: 33497555
Front Oncol. 2021 Sep 30;11:736104
pubmed: 34660299
Cancer Discov. 2020 Aug;10(8):1129-1139
pubmed: 32430388
Ann Oncol. 2020 Jan;31(1):30-40
pubmed: 31912793
Ann Oncol. 2009 Nov;20(11):1842-7
pubmed: 19406901
Lancet Oncol. 2013 Jan;14(1):29-37
pubmed: 23168366
Lancet Oncol. 2020 Apr;21(4):497-507
pubmed: 32164906
Cancers (Basel). 2020 Jul 16;12(7):
pubmed: 32708575
J Clin Oncol. 2008 Apr 20;26(12):2013-9
pubmed: 18421054
N Engl J Med. 2015 May 14;372(20):1909-19
pubmed: 25970050
Lancet Oncol. 2022 Jan;23(1):115-124
pubmed: 34919824
N Engl J Med. 2004 Jun 3;350(23):2335-42
pubmed: 15175435
J Clin Oncol. 2021 Feb 1;39(4):273-284
pubmed: 33503393
N Engl J Med. 2020 Dec 3;383(23):2207-2218
pubmed: 33264544
N Engl J Med. 2021 Jun 24;384(25):2371-2381
pubmed: 34096690
ESMO Open. 2021 Jun;6(3):100156
pubmed: 34044286
J Clin Oncol. 2020 Sep 20;38(27):3175-3184
pubmed: 32749938
Lancet. 2013 Jan 26;381(9863):303-12
pubmed: 23177514
N Engl J Med. 2022 Jul 14;387(2):120-131
pubmed: 35658005
JCO Precis Oncol. 2021 Apr 06;5:
pubmed: 34250391
J Clin Oncol. 2020 Aug 20;:JCO2001225
pubmed: 32816630
ESMO Open. 2017 Jul 29;2(3):e000177
pubmed: 29211816
Clin Colorectal Cancer. 2020 Sep;19(3):219-225
pubmed: 32605718
Front Oncol. 2022 Feb 16;12:826073
pubmed: 35251991
J Clin Oncol. 2012 Oct 1;30(28):3499-506
pubmed: 22949147
Oncologist. 2022 Aug 5;27(8):663-674
pubmed: 35472176
Cancers (Basel). 2021 Jul 31;13(15):
pubmed: 34359764
Oncologist. 2021 Oct;26(10):845-853
pubmed: 34232546
J Clin Oncol. 2022 Aug 10;40(23):2530-2538
pubmed: 35167329
J Clin Oncol. 2022 Jan 10;40(2):161-170
pubmed: 34637336
Cancer Treat Rev. 2020 Jun;86:102023
pubmed: 32474402